Grimes Allison, Mohamed Ashraf, Sopfe Jenna, Hill Rachel, Lynch Jane
UT Health Science Center San Antonio, Department of Pediatrics, San Antonio, TX.
Cook Children's Medical Center, Fort Worth, TX.
J Natl Cancer Inst Monogr. 2019 Sep 1;2019(54):132-138. doi: 10.1093/jncimonographs/lgz022.
Hyperglycemia is a known complication of therapies used in the treatment of childhood cancer, particularly glucocorticoids and asparaginase. It has been linked to increased infection and reduced survival. With more limited data on hyperglycemia during childhood cancer treatment compared with adult cancer, impact on outcomes is less clear in this population. As additional glycemic-altering cancer agents including immune checkpoint inhibitors and targeted therapies make their way into pediatric cancer treatment, there is a more pressing need to better understand the mechanisms, risk factors, and adverse effects of hyperglycemia on the child with cancer. Thus, we utilized a systematic approach to review the current understanding of the incidence, implications, and outcomes of hyperglycemia during childhood cancer therapy.
高血糖是儿童癌症治疗中所用疗法的一种已知并发症，尤其是糖皮质激素和天冬酰胺酶治疗。它与感染增加和生存率降低有关。与成人癌症相比，儿童癌症治疗期间高血糖的数据较为有限，因此其对治疗结果的影响在这一人群中尚不太明确。随着包括免疫检查点抑制剂和靶向疗法在内的更多改变血糖的癌症治疗药物进入儿科癌症治疗领域，更迫切需要更好地了解高血糖对患癌儿童的作用机制、风险因素及不良反应。因此，我们采用了一种系统方法来综述目前对儿童癌症治疗期间高血糖的发生率、影响及治疗结果的认识。
